Cellectis S.A./€ALCLS
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Cellectis S.A.
Cellectis S.A. is a biotechnology company specializing in gene-editing for cancer immunotherapy. It focuses on developing allogeneic CAR-T cell products designed to address various hematological and solid tumors using its proprietary TALEN gene editing technology. Founded in 1999, Cellectis is headquartered in Paris, France, and operates facilities in both France and the United States, enhancing its global research and development capabilities. The company's strategic positioning is characterized by its focus on creating off-the-shelf CAR-T therapies, aiming to reduce the complexity and cost associated with personalized CAR-T treatments, thereby broadening accessibility to advanced cancer therapies.
Ticker
€ALCLS
Sector
Primary listing
PAR
Industry
Biotechnology
Headquarters
Employees
219
ISIN
FR0010425595
Website
Cellectis S.A. Metrics
BasicAdvanced
€99M
-
-€0.53
3.28
-
Price and volume
Market cap
€99M
Beta
3.28
52-week high
€2.17
52-week low
€1.01
Average daily volume
63K
Financial strength
Current ratio
1.672
Quick ratio
0.942
Long term debt to equity
72.437
Total debt to equity
82.808
Interest coverage (TTM)
-7.09%
Profitability
EBITDA (TTM)
-34.841
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-110.57%
Operating margin (TTM)
-96.52%
Effective tax rate (TTM)
-0.43%
Revenue per employee (TTM)
€212,200
Management effectiveness
Return on assets (TTM)
-9.19%
Return on equity (TTM)
-58.55%
Valuation
Price to revenue (TTM)
2.892
Price to book
0.86
Price to tangible book (TTM)
0.86
Price to free cash flow (TTM)
6.292
Free cash flow yield (TTM)
15.89%
Free cash flow per share (TTM)
21.87%
Growth
Revenue change (TTM)
351.26%
Earnings per share change (TTM)
-55.51%
3-year revenue growth (CAGR)
55.96%
10-year revenue growth (CAGR)
5.19%
3-year earnings per share growth (CAGR)
-40.56%
10-year earnings per share growth (CAGR)
5.20%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cellectis S.A. stock?
Cellectis S.A. (ALCLS) has a market cap of €99M as of July 04, 2025.
What is the P/E ratio for Cellectis S.A. stock?
The price to earnings (P/E) ratio for Cellectis S.A. (ALCLS) stock is 0 as of July 04, 2025.
Does Cellectis S.A. stock pay dividends?
No, Cellectis S.A. (ALCLS) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Cellectis S.A. dividend payment date?
Cellectis S.A. (ALCLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Cellectis S.A.?
Cellectis S.A. (ALCLS) has a beta rating of 3.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.